Balipodect (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name TAK-063) is a selective phosphodiesterase 10A (PDE10A) inhibitor which was under development by Takeda for the treatment of schizophrenia.

[1][2][3] It is active in animal models of antipsychotic-like activity, including inhibition of hyperlocomotion induced by the NMDA receptor antagonist dizocilpine (MK-801) or the dopamine releasing agent methamphetamine, inhibition of conditioned avoidance responses, and reversal of prepulse inhibition deficits.

[4] The drug reached phase 2 clinical trials for this indication but its development was discontinued.

[1][2] It was reported to be poorly effective or ineffective for schizophrenia in clinical trials.

[5][6][7]